IGHV3-30

Across TCGA pan-cancer cohorts, IGHV3-30 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGHV3-30 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher IGHV3-30 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV3-30 expression acts as an unfavorable survival marker.

DLBC, LUAD, and LUSC are the cancer types where IGHV3-30 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.118	0.802	.025	12	view →
LUAD	OS	Median	All	0.258	0.812	.004	12	view →
LUSC	OS	Median	All	0.196	0.659	.045	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IGHV3-30–DLBC (OS)

Open the DLBC breakdown →